GTCR / ZENTIVA Merger Cleared
Summary
The European Commission cleared GTCR's proposed acquisition of ZENTIVA under EU Merger Regulation on 27 March 2026. The transaction was reviewed at Phase I under Article 6(1)(b) and received unconditional clearance with no competitive concerns identified. The merger involves pharmaceutical manufacturing activities (NACE C.21).
What changed
The European Commission issued a Phase I clearance decision for GTCR's acquisition of ZENTIVA under Council Regulation 139/2004 (EU Merger Regulation). Case M.12186 was notified on 20 February 2026 with a provisional deadline of 27 March 2026, and the Commission issued a non-opposition decision under Article 6(1)(b) on that date. No remedies, conditions, or commitments were required.
The parties do not need to take any further action as the merger is unconditionally cleared. Companies involved in mergers with EU dimension should ensure notifications are filed timely under Regulation 139/2004. The decision was published in the Official Journal (OJEU C/2026/1290).
Source document (simplified)
M.12186
Merger Subscribe for updates
GTCR / ZENTIVA
Companies: GTCR | ZENTIVA Last decision date: 27.03.2026 Case type: Merger Regulation: Council Regulation 139/2004 Notification date: 20.02.2026 Provisional deadline: 27.03.2026 Economic activities: C.21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE Rev. 2.1) Decisions Art. 6(1)(b) of 27.03.2026 Other case related information Publication in the OJ: OJEU C/2026/1290 of 02.03.2026 Description of the concentration of 20.02.2026: EN published on 23.02.2026
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Consumer Protection alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when EC Competition Cases publishes new changes.